Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated May 25, 2012 (14 years ago)

Furosemide***

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility: Franck's Lab Inc. initiated a recall of all Sterile Human Drugs distributed between 11/21/2011 and 05/21/2012 because FDA environmental sampling revealed the presence of microorganisms and fungal growth in the clean room where sterile products were prepared.

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

FUROSEMIDE*** (25X10ML) 10MG/ML INJECTABLE 250 ML; FUROSEMIDE*** (25X4ML) 10MG/ML INJECTABLE 2 VIAL (2 DIFFERENT PRODUCTS)

Drug: Furosemide

Recalling firm
Franck's Lab Inc., d.b.a. Franck's Compounding Lab
Origin
FL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1525-2012 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Furosemide recalls

See all
Class II · Moderate risk

Furosemide Tablets

CGMP Deviations; presence of N-nitroso-Furosemide (NNF) above the recommended intake limit.

Ongoing Nitrosamine impurity Leading Pharma, LLC NDC 69315-118-01 D-0486-2026
Class II · Moderate risk

Furosemide Tablets USP

Failed Tablet/Capsule Specifications: An unusually thick tablet was reported through a complaint.

Terminated Failed specification Roxane Laboratories, Inc. NDC 0054-4297-31 D-0437-2017

Other recalls by Franck's Lab Inc., d.b.a. Franck's Compounding Lab

All 2012 recalls
Class II · Moderate risk

Ceftriaxone 1 gm/50 mL D5W

Lack of Assurance of Sterility; All lots of sterile products compounded by the pharmacy within expiry are subject to this recall. This recall is initiated due to concerns associated with quality control procedures observed during a recent FDA inspection.

Ongoing Sterility / contamination Franck's Lab Inc dba Trinity Care Solutions D-1482-2014
Class II · Moderate risk

Cefepime 2 gm/100 mL 0.9%NS

Lack of Assurance of Sterility; All lots of sterile products compounded by the pharmacy within expiry are subject to this recall. This recall is initiated due to concerns associated with quality control procedures observed during a recent FDA inspection.

Ongoing Sterility / contamination Franck's Lab Inc dba Trinity Care Solutions D-1481-2014
Class II · Moderate risk

Ceftriaxone 2 gm/100 mL D5W

Lack of Assurance of Sterility; All lots of sterile products compounded by the pharmacy within expiry are subject to this recall. This recall is initiated due to concerns associated with quality control procedures observed during a recent FDA inspection.

Ongoing Sterility / contamination Franck's Lab Inc dba Trinity Care Solutions D-1480-2014
Class II · Moderate risk

Cefepime 1 gm/100 mL 0.9%NS

Lack of Assurance of Sterility; All lots of sterile products compounded by the pharmacy within expiry are subject to this recall. This recall is initiated due to concerns associated with quality control procedures observed during a recent FDA inspection.

Ongoing Sterility / contamination Franck's Lab Inc dba Trinity Care Solutions D-1479-2014